Catalog No.
VVV07503
Species reactivity
Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, RBD, Spike protein S1, S, Receptor-Binding Domain
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
K9N5Q8
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
D12
Designed miniproteins potently inhibit and protect against MERS-CoV., PMID:40450691
Characteristic profiling of CHO-cell expressed MERS-CoV RBD-Fc., PMID:40318720
Structural insights into the receptor-binding domain of bat coronavirus ZXC21., PMID:40306273
Glycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoV., PMID:40266218
A Novel Antibody Against the Non-RBD Region of Middle East Respiratory Syndrome Coronavirus Spike Protein., PMID:40241666
Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608
MERS-CoV spike vaccine-induced N-terminal domain-specific antibodies are more protective than receptor binding domain-specific antibodies., PMID:39898019
A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV., PMID:39669563
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV., PMID:39644492
Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19., PMID:39576992
Designed miniproteins potently inhibit and protect against MERS-CoV., PMID:39574666
Broad cross neutralizing antibodies against sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humans., PMID:39438493
Broad-spectrum coronavirus neutralization induced by hetero RBD-Fc protein vaccine., PMID:39279390
Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge., PMID:39189731
Structure defining of ultrapotent neutralizing nanobodies against MERS-CoV with novel epitopes on receptor binding domain., PMID:39141662
Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans., PMID:39058596
MultiTEP-Based Vaccines Targeting SARS-CoV-2 Spike Protein IgG Epitopes Elicit Robust Binding Antibody Titers with Limited Virus-Neutralizing Activity., PMID:38921817
Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals., PMID:38846944
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses., PMID:38822339
A dual-targeting approach using a human bispecific antibody against the receptor-binding domain of the Middle East Respiratory Syndrome Coronavirus., PMID:38697296
Disposable graphene-oxide screen-printed electrode integrated with portable device for detection of SARS-CoV-2 in clinical samples., PMID:38697015
Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV., PMID:38691025
Antibody-dependent enhancement (ADE) of SARS-CoV-2 in patients exposed to MERS-CoV and SARS-CoV-2 antigens., PMID:38682568
A Host Receptor Nanodisc-Based Biosensor Platform for the Detection of a Specific Virus and Its Variants., PMID:38668735
Potential of a Bead-Based Multiplex Assay for SARS-CoV-2 Antibody Detection., PMID:38666885
Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans., PMID:38617298
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV., PMID:38558973
Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models., PMID:38105421
A Modified Recombinant DNA-Based SARS-CoV-2 Vaccine Expressing Stabilized Uncleavable Spike Protein Elicits Humoral and Cellular Immunity against Various SARS-CoV-2 Variants of Concern., PMID:40303691
A potential broad-spectrum neutralizing antibody against Betacoronavirus., PMID:38078658
Improving antibody optimization ability of generative adversarial network through large language model., PMID:38074472
Individual Immune Response to SARS-CoV-2 Infection-The Role of Seasonal Coronaviruses and Human Leukocyte Antigen., PMID:37887003
Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice., PMID:37858337
Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera., PMID:37794071
Double-antibody-based nano-biosensing system for the onsite monitoring of SARS-CoV-2 variants., PMID:37614970
MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection., PMID:37336390
Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice., PMID:37293083
Enhancing immune protection against MERS-CoV: the synergistic effect of proteolytic cleavage sites and the fusion peptide and RBD domain targeting VLP immunization., PMID:37275866
Development, Validation, and Utilization of a Luminex-Based SARS-CoV-2 Multiplex Serology Assay., PMID:36927068
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease., PMID:36889306
Hyperimmune immunoglobulin for people with COVID-19., PMID:36700518
Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge., PMID:36669119
Close relatives of MERS-CoV in bats use ACE2 as their functional receptors., PMID:36477529
Two formulations of coronavirus disease-19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice., PMID:36444622
Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive protection across divergent subgroups., PMID:36380759
Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein., PMID:36246239
Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses., PMID:36158162
A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein., PMID:36075899
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome., PMID:35853863
Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle vaccine in llamas., PMID:35739576
For research use only. Not for human or drug use.
